Study of Rituximab Plus High-Dose Chemotherapy Poor Prognosis Non-Hodgkin's Lymphoma
Lymphoma, Non-Hodgkin's
About this trial
This is an interventional treatment trial for Lymphoma, Non-Hodgkin's
Eligibility Criteria
Inclusion Criteria: Histologically documented, aggressive and/or intermediate grade and high-grade B cell NHL, CD20 positive. Histologic subtypes include follicular large cell, diffuse small cleaved cell, diffuse mixed small and large cell, diffuse large cell, anaplastic large cell, and mantle cell lymphomas. NHL must have high-intermediate or high International Prognostic Index (standard IPI) score at diagnosis. Mantle cell NHL is eligible regardless of IPI score. Complete or partial response to first-line therapy. Treated CNS or meningeal disease, using radiation therapy and/or intrathecal chemotherapy, is allowed. Patients with meningeal disease must have cytologically negative CSF at time of study entry. Cumulative total doxorubicin: <500 mg/m2 Performance score 0-2 Patients with a prior malignancy are eligible if they were treated with curative intent and have no evidence of active disease. Patients must not be pregnant or nursing. Informed Consent Exclusion Criteria: pregnant or nursing
Sites / Locations
- The University of Michigan